Public advisory - Sabril (vigabatrin) 500 mg sachets found to contain trace amounts of another drug
OTTAWA, ON, Aug. 18, 2023 /CNW/ -
Summary
Product: Sabril (vigabatrin) 500 mg sachets, DIN 02068036, lots 3209710A and 3207333A
Issue: Health products ? Contamination
What to do: Do not stop taking Sabril without consulting your health care professional as stopping this drug comes with serious risks. Unless you have a severe allergy to tiapride, the benefits of this drug are expected to continue to outweigh its potential risks despite the presence of trace amounts of tiapride. Monitor for any new and unexpected side effects. Seek immediate medical attention of you experience symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat. Consult your health care professional if you have any concerns.
Images
Affected products
Product
DIN
Lot number
Expiry date
Sabril (vigabatrin) 500 mg sachets
02068036
Lot 3209710A
Aug-2026
Sabril (vigabatrin) 500 mg sachets
02068036
Lot 3214708A
Feb-2027
Sabril (vigabatrin) 500 mg sachets
No DIN on label (this is a U.S.-labelled lot imported
to help address a current shortage)
Lot 3207333A
Mar-2027
Issue
Lundbeck Canada Inc. has informed Health Canada that two lots of Sabril (vigabatrin) 500 mg powder for oral solution, in sachet format, were found to contain trace amounts of another prescription drug, tiapride.
Sabril is a prescription drug used to manage epileptic seizures in adults and children, and for infantile spasms (West Syndrome).
Health Canada has determined that the health risk of the trace contamination to patients is low. It is important that patients do not stop taking their Sabril as prescribed without consulting their physician, as the benefits of this drug are expected to outweigh its potential risks despite trace amounts of tiapride, unless patients have a severe allergy to tiapride. Sabril therapy should not be interrupted, as this may increase the risk of seizures, which could be life-threatening.
There are no authorized products containing tiapride in Canada. In some other countries, tiapride is a drug used to treat a range of neurological and psychiatric disorders including dyskinesia (involuntary movements), alcohol withdrawal syndrome, psychosis, agitation and aggression in the elderly, and tic disorders in children.
Lundbeck Canada Inc., the Canadian manufacturer of Sabril, is reporting ongoing shortages of this medication and no alternative supply is available in Canada at this time. As a result, Health Canada is not recommending that the company recall this medication at this time. Health Canada continues to monitor the situation.
Health Canada recognizes how important Sabril is for the people taking it. Health Canada is leading work with provincial and territorial governments, manufacturers and stakeholders across the supply chain and healthcare system to mitigate the ongoing shortage of Sabril. This includes accessing additional foreign-authorized supply, where possible.
Although this drug is not being recalled, Health Canada is monitoring the company's implementation of any necessary corrective and preventative actions to prevent this from happening again.
What you should do
Do not stop taking your Sabril medication without consulting your physician.
Monitor for any new and unexpected side effects. Seek immediate medical attention of you experience symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat.
Consult your health care professional if you or your child are taking Sabril and you have any concerns.
Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide. Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead...
At the Summit on Clean Cooking in Africa, World Resources Institute (WRI) and the Clean Cooking Alliance (CCA) announced a strategic partnership to further embed clean cooking into a broad range of sustainable development initiatives across the two...
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...
FIRST QUARTER (JANUARY - MARCH 2024)
Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...